PITTSBURGH, June 9, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced that it has launched Carboplatin
Injection, 50 mg/5 ml, in multi-dose vials, which is the generic
version of Bristol-Myers Squibb's Paraplatin® Injection.
Mylan received final approval from the U.S. Food and Drug
Administration (FDA) for its Abbreviated New Drug Application
(ANDA) for this product, which is indicated for the initial
treatment of advanced ovarian carcinoma in established combination
with other approved chemotherapeutic agents. Mylan also received
final approval for Carboplatin Injection, 150 mg/15 ml, 450 mg/45
ml, 600 mg/60 ml, in multi-dose vials, and intends to launch these
presentations subsequently.
Carboplatin Injection, 50 mg/5 ml, 150 mg/15 ml, 450 mg/45 ml,
and 600 mg/60 ml had U.S. sales of approximately $30.4 million for the 12 months ending
March 31, 2014, according to IMS
Health. This launch bolsters Mylan's growing portfolio of cancer
treatment and supportive care products.
Currently, Mylan has 299 ANDAs pending FDA approval representing
$105.2 billion in annual brand sales,
according to IMS Health. Forty-one of these pending ANDAs are
potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12
months ending Dec. 31, 2013,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.